The expression of miR-222 was significantly up-regulated in the muscle tumor tissues, while the expression levels of two target genes of miR-222, cyclin-dependent kinase inhibitor 1B (CDKN1B) and CDKN1C, were down-regulated in the tumors [147]. The gene discussed is CDKN1C; the disease is neoplasm.